Trading a BCAX straddle lets you take a pure volatility position on Bicara Therapeutics Inc without committing to a direction. Bicara Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate BCAX straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on BCAX profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Bicara Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the BCAX straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the BCAX straddle is the cleanest expression of that view. Our scanner prices every BCAX straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a BCAX straddle into a catalyst or short a BCAX straddle to harvest decay, the options straddle setups that matter are all in one place.
